Roslin Cells Announces New Cell Therapy Manufacturing Contract with Pfizer Inc. Roslin Cells announced that it has signed a contract with Pfizer Inc., acting through Neusentis, a research unit of Pfizer based in Cambridge, UK, to support the manufacture of retinal pigment epithelium cells to be used in a cell therapy clinical trial. This trial will evaluate the therapy for the treatment of patients suffering from age related macular degeneration as part of an ongoing collaboration with The London Project at the Institute of Ophthalmology, UCL. [Roslin Cells] Press Release UCL, Imperial & Cell Therapy Catapult Collaborate to Advance Leukemia Cell Therapy A novel cell therapy approach to the treatment of acute myeloid leukemia is to be developed further via an innovative partnership between the Cell Therapy Catapult, UCL Business and Imperial Innovations. [Cell Therapy Catapult] Press Release Gene Therapy Section Formed within the Alliance for Regenerative Medicine The Alliance for Regenerative Medicine (ARM) and the American Society of Gene & Cell Therapy (ASGCT) announced their partnership. ARM’s new Gene and Gene-Modified Cell Therapy Section brings together the leading gene therapy companies and organizations in the U.S. and Europe to advocate for policies and programs to accelerate the development of new therapeutics to treat and cure a range of diseases for which no effective treatment options are available. [Alliance for Regenerative Medicine] Press Release SKC Partners with UK Charities to Launch International Neuroblastoma Clinical Trial Solving Kids’ Cancer (SKC), the Neuroblastoma Children’s Cancer Alliance, and Joining Against Cancer in Kids awarded its first grant through their INBRACED (International Neuroblastoma Research and Collaboration for Effective Delivery) initiative, which aims to improve access of promising clinical trials for children with high-risk neuroblastoma in North America, the UK and in Europe. The grant amount of $400,000 will create a new immunotherapy treatment option in the U.S., UK, and in Spain, for children with relapsed or refractory disease. [Solving Kids’ Cancer] Press Release Stem Cell Research on Campus Grows after $3 Million Boost Unlocking knowledge about how organisms develop and repair, stem cell research holds great promise for future therapies for injuries and conditions, from infertility and Alzheimer’s to heart failure and cancer. As part of its mission to promote cross-campus interactions and enhance training in stem cell biology at Cornell, the Cornell Stem Cell Program held its second Stem Cell Retreat on campus. [Cornell University] Press Release SLU Virologists Harness Adenovirus to Kill Breast Cancer Cells With a $40,250 grant from the Lottie Caroline Hardy Charitable Trust Fund, researchers at Saint Louis University (SLU)’s Institute for Molecular Virology will study a small fragment of adenovirus as a possible future therapy for HER2 breast cancer. [Saint Louis University] Press Release Ground Breaking Hip and Stem Cell Surgery in Southampton Doctors and scientists in Southampton have completed their first hip surgery with a 3D printed implant and bone stem cell graft. The 3D printed hip, made from titanium, was designed using the patient’s CT scan and CAD CAM (computer aided design and computer aided manufacturing) technology, meaning it was designed to the patient’s exact specifications and measurements. [University of Southampton] Press Release TxCell’s Col-Treg Receives Advanced Therapy Medicinal Product Classification from EMA TxCell SA announced that Col-Treg, its second therapeutic candidate from its ASTrIA platform, has been granted Advanced Therapy Medicinal Product classification by the Committee for Advanced Therapies of the European Medicines Agency (EMA). [TxCell SA] Press Release |